📅 Last Updated: July 2026
Key Summary: Rejuran (PN, salmon-derived), Juvelook (PDLLA + HA, synthetic), and Re2O (human ECM) are not competing versions of the same treatment. They put different materials into your skin and ask it to do different work. No head-to-head trial exists between them — anyone ranking them is describing marketing sequence, not evidence.
1. What's Actually in the Syringe
| Category | Rejuran | Juvelook | Re2O |
|---|---|---|---|
| Material | PN — polynucleotide | PDLLA + HA | Human ECM (hADM) |
| Source | Salmon DNA (O. keta) | Synthetic polymer | Donated human dermis |
| Manufacturer | PharmaResearch | VAIM Global | L&C Bio |
| Regulatory class | Medical device | Medical device | Human tissue |
| Available outside Korea | Yes — EU MDR approved | Yes — CE, 60+ countries | Effectively no |
That last row is the one most people miss. We'll come back to it.
2. What Each One Asks Your Skin to Do
Rejuran — Sends a Repair Signal
PharmaResearch describes PN as a tissue repair stimulator. Once injected, polynucleotides act as a repair signal inside the skin — attracting water to hydrate tissue and creating an environment for skin cells to regenerate, while supporting fibroblasts, the cells that produce collagen and elastin.
The company describes PN and PDRN as regenerative medicine raw materials composed of DNA fragments isolated from salmon sperm cells, with PN having a longer nucleic acid chain than PDRN.
The logic: your cells are capable — they just need to be told.
Per the manufacturer's line-up: Rejuran Healer for general texture and elasticity, Rejuran HB+ for hydration-focused indications, Rejuran I for the periorbital area at lower concentration with a finer needle.
Juvelook — Builds a Controlled Construction Site
VAIM positions Juvelook as a hybrid: the HA component delivers immediate hydration and radiance, while collagen stimulated by the PDLLA develops gradually over the following weeks.
The particle design is the notable part. VAIM patented a PDLLA manufacturing process producing a porous, reticular mesh microparticle structure — a design the company says maximises surface area for collagen induction while minimising the nodule risk historically associated with polylactic acid injectables. Unlike PLLA's crystalline particles, which can trigger granulomas if injected imprecisely, PDLLA uses amorphous round particles.
The logic: provoke the skin carefully, and it rebuilds. The result comes from the reaction, not the material.
Re2O — Supplies the Material Itself
Re2O neither signals nor provokes. It places human extracellular matrix into the dermis.
Per the Yonsei University clinical paper (Int J Mol Sci 2026;27(5):2193), composition is approximately 80% collagen, 3% elastin, 0.4% sGAG, with residual DNA under 50 ng/mg. Electron microscopy confirmed that after micronisation, collagen fibril alignment and the characteristic D-banding pattern were preserved — the ECM architecture survived being turned into particles.
In rat models, fibroblasts migrated into the injected matrix within one week, with new collagen forming at the matrix–host interface.
The logic: if the scaffold itself has collapsed, supply scaffold.
3. Three Different Bets
Strip away the branding, and each product is a wager about what's wrong:
| Product | The bet |
|---|---|
| Rejuran | Your cells are underperforming → signal them |
| Juvelook | Your skin rebuilds if provoked → provoke it precisely |
| Re2O | Your structural material is depleted → supply material |
None of these bets has been tested against the others. Re2O's only randomised trial used non-crosslinked hyaluronic acid as the comparator — not Rejuran, not Juvelook. The other two have their own trials against their own comparators.
Three coherent theories, three separate evidence bases, zero direct comparisons. That is the honest state of this field in 2026.
4. What Each Manufacturer Positions Their Product For
We can't tell you which is better. We can tell you what each company says theirs is for — and let you notice they're aiming at different targets.
Rejuran (PharmaResearch): skin texture, elasticity, hydration, periorbital fine lines — sub-products differentiated by area and concentration.
Juvelook (VAIM): the 50mg version targets skin quality; Volume (200mg) targets deeper volumising. Typically a course of 3 sessions at 1-month intervals. Finer particles suit delicate, superficial areas — under-eye, fine lines around the mouth.
Re2O (L&C Bio): dermal density, volume, elasticity, pore area, wrinkle depth, barrier function, pigmentation. The Yonsei trial measured all of these against HA and found significant differences at multiple timepoints. Line-up splits by particle size: 100㎛ standard for thicker areas, ~50㎛ Fine for thin skin.
Read those three again. They are not describing the same job.
5. Timelines Differ — And This Matters If You're Flying
| Onset | Practical implication | |
|---|---|---|
| Rejuran | 3–4 sessions, 2–4 weeks apart | Requires multiple visits |
| Juvelook | 3 sessions at 1-month intervals | HA gives early effect; collagen follows |
| Re2O | Trial data through 20 weeks; month 3 is the equalising point | Slowest to declare itself |
That last row deserves emphasis, and it's the part most clinics leave out.
The 202-patient randomised trial of micronised ADM (Aesth Plast Surg 2026;50:3710–19) found that at six weeks, patient satisfaction was significantly lower than the collagen filler comparator (67.4% vs 83.9%) — with early pain at 40.7% versus 10.1%, and swelling at 45.4% versus 13.5%. By three months the difference had vanished and outcomes were equivalent (88.4% vs 85.4% at 3 months; 70.9% vs 69.7% at 6 months).
The authors attribute the early reactions to physics, not biology: mADM particles must be dense and rigid to provide mechanical scaffolding, which requires 23G or 25G needles instead of 27G. Of the adverse local events, 78% resolved without any treatment.
If you fly home at week four, you will be at the worst point of the curve. That is not a complication. That is the timeline. But few people are told, which is why some conclude they were scammed when they weren't.
6. The Row You Skipped: Availability
Look at the table in Section 1 again.
Rejuran travels. It is the only PN-based medical device approved under EU Medical Device Regulation, with a European distribution agreement spanning 22 countries including the UK, Germany, France, Italy and Spain.
Juvelook travels. MFDS approval in Korea, CE certification in Europe, Thailand FDA approval — though it is not cleared for use in the United States.
Re2O doesn't travel — and this isn't a marketing claim.
Re2O is not classified as a medical device. In Korea it is regulated as human tissue. Medical devices obtain per-product approval for stated indications and export through device pathways. Human tissue moves through an entirely different framework: donor consent, tissue bank accreditation, lot-level traceability, and national import rules that differ everywhere.
The Yonsei researchers note plainly that clinical studies investigating injectable hADM as a primary dermal scaffold were, until their paper, absent. The category is new, and the regulatory route it travels is one most countries have not built for cosmetic use.
The practical situation: you can get PN and PDLLA in London, Bangkok, or Milan. Human-ECM boosters, in this form, essentially only exist where the tissue framework permits them. That is Korea.
This is also why Korea is currently tightening its rules. As of March 2026, the MFDS is reviewing legislation to restrict cosmetic advertising of human tissue products and to require that patients be told when a product is human-tissue derived.
A country writing stricter rules about a category is not a country to be nervous about. It is the opposite. (We unpack why Korea reaches certain treatments first — and what's genuinely Korea-only versus not — in Why Some Treatments Reach Korea First.)
7. So Which One?
Here is where most articles give a fake answer. We'll give you a real boundary instead.
What the evidence supports saying:
- These materials do different things — established
- Manufacturers position them for different targets — documented above
- Re2O outperformed non-crosslinked HA across multiple parameters — Yonsei RCT, n=20, 20 weeks
- Micronised ADM matched collagen filler at 3 and 6 months with less volume and fewer top-ups, but more early reactions — 202-patient RCT
What no evidence supports anyone saying:
- That one is better than another
- That there is a generational hierarchy
- That any of them is right for a patient nobody has examined
### How We Approach This at DIORE
There is no product answer. There is only a face.
Dermal thickness varies across a single cheek. A patient can need scaffolding at the temple and signalling at the periorbital area — in the same session, in the same face. Pore-dominant and laxity-dominant skin can look identical in a photograph and require opposite answers.
This is why we don't quote a product before examining you. Not as a policy stance — because it isn't possible. The information needed to answer the question doesn't exist until we are looking at your skin in person.
If a clinic can tell you which booster you need from a photo or a message, they aren't diagnosing. They're taking an order.
FAQ
Which is best?
No study has compared them directly. Anyone answering this question is guessing or selling.
Can I get Re2O in my country?
Almost certainly not — not because of exclusivity, but because human tissue products move through a regulatory framework most countries haven't extended to aesthetics. Rejuran and Juvelook, by contrast, are available across Europe and much of Asia.
Is human-derived tissue safe?
The source material has a long reconstructive history. L&C Bio states the tissue comes from US donors who consented to cosmetic use, with AATB accreditation, FDA listing of the raw material, MFDS approval, viral inactivation, and mandatory lot-number recording at implantation. If the concept still makes you uncomfortable, that is a legitimate reason to choose something else — tell us and we'll plan around it.
Can I combine them?
Sequencing and intervals depend on your skin and your travel schedule. It's a consultation question, not a menu question.
How long does Re2O last?
Published follow-up ends at 20 weeks. Beyond that, nobody knows — including us. Any clinic quoting a longer figure should be asked for their source.
This content is for information only. Results vary between individuals. All procedures require consultation with a physician.
DIORE Clinic | Premium Aesthetic Clinic, Seoul
Head Doctor Direct Treatment · Personalized 1:1 Consultation
